PMID: 9184407May 1, 1997Paper

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B

Thrombosis and Haemostasis
D LilesK Brinkhous

Abstract

Current therapy for hemophilia B requires large intravenous doses of factor IX (F.IX) given in the clinic or at home. Although home therapy is possible for many patients, it is often complicated by factors such as the lack of good venous access. Very little is known about extravascular routes for administering proteins like F.IX (57 kD) or other vitamin K-dependent procoagulant factors into the circulation. Questions about the absorption rate from extravascular administration as well as plasma recovery and bioavailability have arisen recently with the growing availability of highly purified procoagulant proteins and increased interest in gene therapy of hemophilia B. Therefore, a group of studies were undertaken to determine the absorption rate, plasma recovery, and bioavailability of high purity, human plasma-derived F.IX concentrates administered via extravascular routes in hemophilia B dogs and in one human hemophilia B subject. Five hemophilia B dogs were given human F.IX via either a subcutaneous (s.c.), intramuscular (i.m.), intraperitoneal (i.p.) or intravenous (i.v.) route. In a subsequent study, a single SC administration of human F.IX was compared to an identical i.v. dose of F.IX in the human hemophilia B subject. Al...Continue Reading

Citations

May 24, 2012·The AAPS Journal·Wolfgang F RichterMarilyn E Morris
May 23, 2013·Journal of Thrombosis and Haemostasis : JTH·A R BrooksJ E Murphy
Jan 10, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·Q ShiR R Montgomery
Apr 15, 2011·Journal of Thrombosis and Haemostasis : JTH·A TiedeE Berntorp
Jul 17, 2013·Haemophilia : the Official Journal of the World Federation of Hemophilia·K TatsumiT Okano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.